Webinar Preview
The availability of disease-modifying treatments (DMTs) for early symptomatic Alzheimer’s disease (AD) has vastly increased the need for clinical AD biomarker testing. Blood biomarkers help in determining whether cognitive impairment is caused by AD. Biomarker evidence of amyloid pathology is essential prior to initiation of DMTs.
This webinar will review the types of blood biomarker tests for AD that are clinically available: amyloid positron emission tomography (PET) and AD blood tests. The Imaging Dementia – Evidence of Amyloid Scanning (IDEAS study) was a community-based research study that used PET scans to detect amyloid pathology. A subset of patients in the IDEAS study also received AD blood biomarkers.
In this webinar, the speakers will discuss the real-world use of PET scans and review the concordance of the PrecivityAD2™ blood test with amyloid PET scans and cerebrospinal fluid (CSF) tests.
Register for this webinar today to understand the critical role of blood biomarkers in Alzheimer’s disease diagnosis and management.
Speakers
Dr. Gil Rabinovici, MD, PhD, Professor, Department of Neurology, Memory & Aging Center, UCSF
Dr. Gil Rabinovici, a distinguished neurologist at UCSF, specializes in memory disorders and brain health in older adults. With degrees from Stanford and Northwestern, he leads groundbreaking research in dementia diagnostics and neurodegenerative diseases, aiming to expedite drug development. Recognized internationally, he directs UCSF’s Alzheimer’s Research Center and chairs major studies on PET imaging’s role in cognitive disorders.
Message Presenter
Dr. Joel Braunstein, MD, MBA, Co-Founder and CEO, C2N Diagnostics
Dr. Joel Braunstein is the Co-Founder and CEO of C2N Diagnostics and has led the company’s commercial growth since its inception. Dr. Braunstein has played a senior executive role in numerous emerging life sciences companies since 2004. He received his MD with highest distinction from Northwestern University Medical School in 1996.
Subsequently, he trained in internal medicine at Brigham and Women’s Hospital, Harvard Medical School, and was a Fellow in Cardiovascular Medicine and Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions. Additionally, he completed an MBA with a Management and Health Policy focus and maintained an Assistant Professorship in Cardiology at Johns Hopkins University. In 2010, he was named a Distinguished Alumnus of Johns Hopkins University. Dr. Braunstein also serves on the Executive Advisory Board for the Chemistry of Life Processes (CLP) Institute at Northwestern University.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Neurologists
- Primary Care Physicians
- Internal Medicine Physicians
- Gerontologists
- Geriatricians
- Dementia Care Specialists
What You Will Learn
Attendees will learn about:
- Lessons learned from IDEAS: Real-world performance and utility of amyloid PET scans in a prospective clinical care study of US Medicare beneficiaries with cognitive impairment
- PrecivityAD2™ blood test performance compared to PET scans and CSF tests for the evaluation of amyloid pathology in patients presenting with signs or symptoms of mild cognitive impairment or dementia
- The importance of pathological biomarker ratios in mitigating differences in quantitative measurements related to age, sex, ethnicity, race and comorbidities
Xtalks Partner
C₂N Diagnostics
C₂N Diagnostics, LLC (C₂N) is a specialty diagnostics company that strives to provide exceptional laboratory services and products in the field of brain health. C₂N’s high-resolution mass spectrometry-based biomarker services and products are used for clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C₂N assays have been used in over 100 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies. C₂N has ongoing collaborations with multi-national pharmaceutical and biotech companies. Over 15,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account